In addition, TP53 mutations can be detected in up to 20-30% of patients with CLL [17], which implies that, in the remaining cases, possibly other alterations in the p53 pathway may be involved in CLL. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.